Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | GALR3 | O60755 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5848074 | 0.79 | SIRT2 (0.41) | MAPTALOX5SMN1; SMN2NPC1RAB9A | |
| SCHEMBL13857793 | 0.77 | TP53 (0.39) | MAPTALOX5SMN1; SMN2NPC1MEN1 | |
| SCHEMBL557225 | 0.76 | MEN1 (0.38) | MAPTALOX5SMN1; SMN2MEN1GALR3 | |
| SCHEMBL3325221 | 0.73 | MEN1 (0.35) | MAPTSMN1; SMN2NPC1RAB9AMEN1 | |
| SCHEMBL2698628 | 0.73 | PTPRC (0.45) | ALOX5SMN1; SMN2HTTKMT2AALDH1A1 | |
| SCHEMBL1608761 | 0.72 | ALDH1A1 (0.40) | ALDH1A1 | |
| SCHEMBL77037 | 0.66 | TSHR (0.44) | MAPTSMN1; SMN2MEN1HTTKMT2A | |
| SCHEMBL2310364 | 0.65 | ALDH1A1 (0.34) | MAPTMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL2700555 | 0.64 | TSHR (0.42) | MAPTSMN1; SMN2NPC1RAB9AMEN1 | |
| SCHEMBL858908 | 0.64 | HCAR3 (0.46) | MAPTSMN1; SMN2NPC1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050043313-A1 | Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION | 2005-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043313-A1 | Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade | TFPI, TFPI2, PLAT | MAPT 4321/4885ALOX5 567/4885SMN1; SMN2 4251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.